MedTrace Logo

Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

NCT00252044 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2005-11-21

No results posted yet for this study

Summary

Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance on the cognitive tasks, with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo.

Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed by pergolide for four weeks.

Conditions

  • Schizotypal Personality Disorder
  • Other Personality Disorders

Interventions

DRUG

Pergolide

Sponsors & Collaborators

  • Bronx VA Medical Center

    lead FED

Principal Investigators

  • Larry J Siever, MD · Bronx VA Medical Center/Mount Sinai School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252044 on ClinicalTrials.gov